Annals of Oncology 15:653-660, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Hematopoetic stem cell transplantation for solid tumors in Europe
Received 11 November 2003; accepted 23 December 2003Background:
Hematopoetic stem cell transplants (HSCT) are discussed as treatment options for patients with solid tumors. Transplant numbers have changed substantially over the last decade, few controlled studies are available and different opinions prevail. Objective information on current practice is needed.
Patients and methods:
Data from 27 902 HSCT for solid tumors (2% allogeneic, 98% autologous), collected by the European Group for Blood and Marrow Transplantation (EBMT) activity survey from 1991 to 2002 were used to assess trends, transplant rates and coefficient of variation of transplant rates in Europe.
Results:
Transplant numbers increased from 536 in 1991 to 4154 in 1997 and decreased to 1913 in 2002. Indications were neuroblastoma (2504 HSCT; 9%), glioma (662 HSCT; 2%), soft tissue sarcoma (1253 HSCT; 4%), germ cell cancer (3291 HSCT; 12%), breast cancer (13 524 HSCT; 48%), Ewing’s sarcoma (1896 HSCT; 7%), lung cancer (387 HSCT; 1%), ovarian cancer (845 HSCT; 3%) and other solid tumors (3540 HSCT; 14%). Allogeneic cells were used in <20 cases up to 1997; since then allogeneic HSCT increased to 159 in 2002, mainly for renal cell carcinoma. Low coefficients of variation in transplant rates (<60%) are observed for Ewing’s sarcoma (<56.5%), suggesting consensus for this indication.
Conclusions:
These data give an overview on current practice of HSCT for solid tumors in Europe. They provide objective information for health-care providers and patient counselling.
1 Division of Hematology, Department of Internal Medicine, Kantonsspital Basel, Switzerland; 2 EBMT Office, Ankara University Medical School, Ibn-i Sina Hospital, Sihhiye, Ankara, Turkey; 3 Oncology–Hematology Department, Ospedale Civile, Ravenna; 4 Department of Pediatric Hematology & Oncology, Institute G. Gaslini, Genova, Italy; 5 BMT Unit, St Anna Kinderspital, Vienna, Austria; 6 EBMT Secretariat, Hospital Clinic, Barcelona, Spain
Key words: donor type, Europe, hematopoetic stem cell transplants, solid tumors, transplant rates
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P Pedrazzoli, J. Ledermann, J-P Lotz, S Leyvraz, M Aglietta, G Rosti, K. Champion, S Secondino, F Selle, N Ketterer, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults Ann. Onc., October 1, 2006; 17(10): 1479 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. McTiernan, D. Driver, M. P. Michelagnoli, A. M. Kilby, and J. S. Whelan High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours Ann. Onc., August 1, 2006; 17(8): 1301 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Barkholt, M. Bregni, M. Remberger, D. Blaise, J. Peccatori, G. Massenkeil, P. Pedrazzoli, A. Zambelli, J.-O. Bay, S. Francois, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe Ann. Onc., July 1, 2006; 17(7): 1134 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kami, A. Makimoto, Y. Heike, and Y. Takaue Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Childs Evolving trends in hematopoietic cell transplantation for solid tumors: tempering enthusiasm with clinical reality Ann. Onc., April 1, 2004; 15(4): 543 - 544. [Full Text] [PDF]
|
|